Recently, CD19-targeted CAR T cells treatment was shown to induce clinical remission with a decrease in proteinuria in a patient with refractory SLE, where the expansion of CAR T cells preceded the complete and sustained depletion of circulating B cells, resulting in a decrease in anti-dsDNA autoantibodies level (47). This evidence concerns the gene CD19 and systemic lupus erythematosus.